)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
Acurx Pharmaceuticals (ACXP) investor relations material
Acurx Pharmaceuticals Q2 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q2 2025 earnings summary12 Aug, 2025
Executive summary
Announced a new Indian patent for DNA polymerase IIIC inhibitors, supporting preclinical antibiotic development for MRSA, VRE, DRSP, and anthrax, and published positive Phase 2b/2d ibezapolstat data in C. difficile infection.
Lead candidate ibezapolstat is advancing toward Phase 3 trials for C. difficile infection, with positive regulatory feedback from EMA and FDA.
No product revenue generated to date; operations funded through equity offerings, warrant inducements, and a $12M equity line of credit.
Implemented a 1-for-20 reverse stock split in August 2025 to maintain Nasdaq listing compliance.
Collaboration with Leiden University Medical Center presented new mechanism of action data for polymerase IIIC inhibitors at a major scientific conference.
Financial highlights
Ended Q2 2025 with $6.1M in cash, up from $3.7M at year-end 2024; working capital was $3.6M.
Q2 2025 net loss was $2.2M ($1.89/share), improved from $4.1M ($5.21/share) in Q2 2024; six-month net loss was $4.4M ($4.01/share), down from $8.5M ($10.84/share) year-over-year.
R&D expenses for Q2 2025 were $0.5M, down from $1.8M in Q2 2024; G&A expenses were $1.7M, down from $2.3M.
Raised $3.4M in Q2 2025 through equity and warrant transactions; net cash provided by financing activities for H1 2025 was $6.1M.
Accumulated deficit reached $71.7M as of June 30, 2025.
Outlook and guidance
Current cash resources are not sufficient for at least 12 months; additional financing is required.
Ongoing multi-step capital raising strategy includes financings, warrant inducements, and public-private partnerships.
Cash burn rate reduced to ~$400K/month, with expectations to maintain this trend.
Preparing to initiate international Phase 3 trials for ibezapolstat, pending financing.
Partnership discussions, including with government agencies, are ongoing and may extend into 2026.
When does the Indian patent for DNA polymerase IIIC inhibitors expire?
What is the current monthly cash burn rate?
Any feedback from physicians on Phase IIb data publication?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Acurx Pharmaceuticals earnings date
Q3 202512 Nov, 2025
Next Acurx Pharmaceuticals earnings date
Q3 202512 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
)
Edge19 Sep 2025
American Express: An Empire of Plastic
How history, brand, and structure have steadily built American Express' moat, and why Warren Buffett still calls it a one-of-a-kind business.
Frequently asked questions
Acurx Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company focused on developing antibiotic treatments for bacterial infections. The company's research and development efforts are primarily centered on addressing antibiotic resistance, targeting bacterial pathogens that pose a significant threat to public health. Acurx utilizes a novel approach to inhibit bacterial DNA synthesis, working to combat infections that are increasingly resistant to traditional antibiotics. Its pipeline includes various antibiotic candidates aimed at providing new therapeutic options for patients. The company is headquartered in Staten Island, New York, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage